

# Fiscal Third Quarter 2026

May 2026





# Disclaimer

This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial instruments of the Company or any of its affiliates, and shall not form the basis of any contract, nor shall it be construed in any manner as a commitment on the part of any person to proceed with any transaction. Any reproduction of this Presentation, in whole or in part, or the disclosure of its contents, without the prior consent of the Company is prohibited. By accepting this Presentation, each recipient agrees to use this Presentation for the sole purpose of evaluating.

## Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company’s Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

## Industry and Market Data

Unless otherwise noted, the forecasted industry and market data contained in the assumptions for the projections are based upon the Company’s management estimates and industry and market publications and surveys. The information from industry and market publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not independently verified any of the data from third-party sources, nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, none of the Company, its affiliates, their respective directors, officers, employees, members, partners, shareholders or agents makes any representation or warranty with respect to the accuracy of such information. These materials are highly sensitive and confidential and being supplied to you solely for your information and for use in this Presentation.

## Financial Information Presentation

Historical financial information of Bioceres has been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). Investors should note that IFRS differs from generally accepted accounting principles in the United States (“US GAAP”), and investors should consult their own professional advisors for an understanding of the difference between IFRS and US GAAP and how those differences might affect such financial statements.

In January 2026, the Company’s Pro Farm Group (PFG) business was subject to a foreclosure auction and has been classified as discontinued operations. Accordingly, unless otherwise indicated, the financial results discussed below reflect the Company’s continuing operations for all periods presented, and prior-year amounts have been recast to exclude the PFG business.

## Use of Non-IFRS Financial Measures

This Presentation includes certain non-IFRS financial measures. These non-IFRS measures are an addition, and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS and neither should be considered as an alternative to net income or any other performance measures derived in accordance with IFRS or as an alternative to cash flows from operating activities as a measure of our liquidity.

The Company believes that these non-IFRS measures of financial results provide useful supplemental information to investors about the Company and its results. The Company’s management uses these non-IFRS measures to evaluate the Company’s financial and operating performance and make day-to-day financial and operating decisions. The Company also believes that these non-IFRS measures are helpful to investors because they provide additional information about trends in the Company’s core operating performance prior to considering the impact of capital structure, depreciation, amortization and taxation on its results. However, there are a number of limitations related to the use of these non-IFRS measures and their nearest IFRS equivalents.

For example, other companies may calculate non-IFRS measures differently or may use other measures to calculate their financial performance, and therefore the Company’s non-IFRS measures may not be directly comparable to similarly titled measures of other companies.

In this presentation, we discuss non-IFRS measures as forward-looking non-IFRS measures.

## Copyrights and Trademarks


All materials contained in this Presentation are protected by copyright laws and may not be reproduced, republished, distributed, transmitted, displayed, broadcast or otherwise exploited in any manner. This Presentation contains trademarks, service marks, and trade names belonging to the Company, its affiliates and other entities and cannot be used without express written consent. Trademarks, service marks, copyrights and trade names referred to in this Presentation, including logos, may appear without the ®, © or TM symbols, but the lack of such symbols is not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other entities’ trademarks, service marks, copyrighted material or trade names to imply a relationship or affiliation with, or endorsement or sponsorship of, the Company by any other entities or persons



# Key Business & Financial Highlights

- **Total revenues were \$39.4 million in 3Q26**, a 23% year-over-year decline, reflecting softer demand and competitive pressures in Crop Protection, together with the ongoing transition in Seeds. Crop Nutrition revenues increased 15% during the quarter.
- **Gross profit was \$12.7 million**, with gross margin of 32%, reflecting lower revenues and product mix effects across segments. Crop Nutrition results were impacted by a non-recurring obsolescence adjustment in inoculants related to inventory normalization efforts.
- **SG&A expenses declined 16% year over year**, reflecting continued execution of organizational streamlining and cost management initiatives across the continuing operations.
- **Net loss was \$10.0 million and Adjusted EBITDA<sup>1</sup> was \$(0.6) million**, primarily reflecting lower gross profit and the absence of prior-year non-cash income associated with the reorganization in Seeds.
- Following the Pro Farm foreclosure auction earlier this year, the **Company continued advancing liability management initiatives across its operating subsidiaries**, including debt reprofiling efforts and a voluntary bond maturity extension process in Argentina.

1. Please refer to "Use of non-IFRS financial information" for information our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure.





# Litigation Update

---

→ Jasper Lake Ventures One LLC, et al. v. Bioceres Crop Solutions Corp., et al. (Index No. 659704/2025)

---

→ Plaintiffs allege defaults under NPAs (August 2022) and amendments thereto (June 2025)

---

→ Foreclosure auction of Pro Farm Group, Inc. assets occurred on January 20, 2026

---

→ Counterclaims and third-party claims include breach of contract, breach of fiduciary duties, fraudulent inducement, and others

---



# Ezequiel Simmermacher

## Appointed Chief Financial Officer

- Executive with nearly 20 years of experience in agribusiness and commodities across South America
- Former senior finance and operational executive at CHS Inc. and Monsanto
- Broad expertise across finance leadership, treasury, operational excellence, and business transformation
- Holds an Executive MBA from IAE Business School and an Industrial Engineering degree from Instituto Tecnológico de Buenos Aires (ITBA)





# Pro Farm Foreclosure Impact on Financial Statements

→ Results of the discontinued operation are presented separately from continuing operations in financial statements

→ Based on the expected proceeds from the foreclosure auction, we recognized an impairment loss to reflect this measurement

→ The cumulative loss recognized amounted to \$179.0 million



- Working capital reduction was \$16.5 million
- PP&E reduction was \$12.2 million
- Intangibles reduction was \$165.2 million
- Total liabilities reduction was \$27.4 million

*(\$ Million)*

Net assets reclassified as subject to foreclosure	194.0
Consideration offered from noteholders	(15.0)
<b>Net loss from foreclosure</b>	<b>179.0</b>





# 3Q26 Revenue by Segment



- Key Drivers**
- Crop Protection affected by softer demand dynamics and competitive pressures
  - Seeds performance reflects lower seed and grain sales during ongoing portfolio transition
  - Crop Nutrition growth driven by microbeaded fertilizers
  - Quarterly performance reflects market headwinds and portfolio transition effects



# 3Q26 Gross Profit by Segment




- Key Drivers**
- Gross profit performance reflected lower revenues, product mix effects and inoculants obsolescence adjustments
  - Crop Protection margin impacted by lower adjuvant participation within product mix
  - Seeds gross margin expanded on improved mix and higher contribution from seed treatment packs
  - Crop Nutrition performance impacted by a non-recurring inoculants obsolescence adjustment
  - Excluding the inoculants adjustment, underlying gross margin performance remained broadly stable year over year



# 3Q26 Adjusted EBITDA<sup>1</sup>

- Underlying Adj. EBITDA<sup>1</sup> performance reflected lower gross profit, partially offset by continued operating expense reductions and improved JV results
- Year-over-year comparison was additionally impacted by the absence of prior-year non-cash income associated with the reorganization in Seeds.





1. Please refer to “Use of non-IFRS financial information” for information regarding our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure.

2. Gross profit and operating expenses excluding D&A, stock-based compensation and transaction expenses.



# Balance Sheet & Cash Position

- Total Financial Debt remained broadly stable quarter over quarter at \$228.8 million
- Management continued advancing liability management initiatives, including bank debt reprofiling discussions and local bond maturity extension efforts in Argentina
- Net Financial Debt remained stable at \$214.0 million, reflecting continued focus on working capital discipline and cash management



● Net Debt    ● Current Debt    ● Non-current Debt    ● Cash & Equivalents<sup>2</sup>

1. Please refer to “Use of non-IFRS financial information” for information regarding our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure.

2. Cash & Equivalents include other cash management short-term investments.



# Ongoing Strategic and Operational Initiatives

## Strategic review of continuing operations

- Assessment of portfolio composition, legal entity simplification, segment structure, tax efficiency and long-term strategic fit across businesses.
- External advisor retained to support strategic planning and organizational review, leveraging deep industry and operating experience.

## Internal risk, governance and compliance processes

- External review of all internal risk, governance and compliance processes.
- Focus on strengthening controls, oversight and Board-level reporting frameworks.

## Rizobacter debt reprofiling

- Process under way, with significant progress achieved to date.
- Includes voluntary extension discussions with bondholders and continued coordination with key banking partners to improve maturity profile and financial flexibility.

Focus on operational discipline, simplification and preservation of long-term strategic value across the platform

# Exhibits





# Unaudited Consolidated Statement of Comprehensive Income

	Three-month period ended 03/31/2026	Three-month period ended 03/31/2025
<b>Continuing operations</b>		
Revenues from contracts with customers	38.2	50.1
Initial recognition and changes in the fair value of biological assets at the point of harvest	1.2	1.0
Cost of sales	(26.7)	(33.0)
<b>Gross profit</b>	<b>12.7</b>	<b>18.1</b>
<i>% Gross profit</i>	32%	35%
Operating expenses	(18.0)	(21.3)
Share of profit of JV	0.5	(0.9)
Change in net realizable value of agricultural products	(0.2)	(0.2)
Other income or expenses, net	0.7	8.8
<b>Operating profit</b>	<b>(4.3)</b>	<b>4.3</b>
Financial result	(9.7)	(5.6)
<b>Profit/(loss) before income tax</b>	<b>(14.1)</b>	<b>(1.2)</b>
Income tax	4.0	3.6
<b>Profit/(loss) for the period from continuing operations</b>	<b>(10.0)</b>	<b>2.3</b>
<b>Discontinued operations</b>		
Loss for the period from discontinued operations	-	(3.9)
<b>Loss for the period from discontinued operations</b>	<b>-</b>	<b>(3.9)</b>
<b>Other comprehensive profit/loss</b>	<b>0.3</b>	<b>(0.8)</b>
<b>Total comprehensive profit/(loss)</b>	<b>(9.7)</b>	<b>(2.4)</b>
<b>Profit/(loss) for the period of continuing operations attributable to</b>		
Equity holders of the parent	(9.0)	2.6
Non-controlling interests	(1.1)	(0.3)
	<b>(10.0)</b>	<b>2.3</b>
<b>Weighted average number of shares</b>		
Basic	63.6	62.8
Diluted	63.6	62.8



# Unaudited Consolidated Statement of Financial Position

<b>ASSETS</b>	<b>31/03/2026</b>	<b>30/06/2025</b>
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	14.4	32.7
Other financial assets	0.5	2.0
Trade receivables	136.3	165.9
Other receivables	13.0	15.9
Recoverable income tax	1.4	1.9
Inventories	48.4	87.6
Biological assets	4.4	2.4
Assets subject to foreclosure	42.4	-
<b>Total current assets</b>	<b>260.7</b>	<b>308.3</b>
<b>NON-CURRENT ASSETS</b>		
Other financial assets	0.0	0.0
Trade receivables	4.8	2.5
Other receivables	25.7	23.7
Recoverable income tax	0.0	0.0
Deferred tax assets	6.5	4.9
Investments in joint ventures and associates	40.6	39.4
Investment properties	-	0.6
Property, plant and equipment	60.0	74.6
Intangible assets	83.9	181.2
Goodwill	36.1	112.2
Right of use asset	11.4	16.4
<b>Total non-current assets</b>	<b>268.9</b>	<b>455.3</b>
<b>Total assets</b>	<b>529.6</b>	<b>763.6</b>

<b>LIABILITIES</b>	<b>31/03/2026</b>	<b>30/06/2025</b>
<b>CURRENT LIABILITIES</b>		
Trade and other payables	79.6	96.4
Borrowings	66.4	119.7
Employee benefits and social security	3.6	6.2
Deferred revenue and advances from customers	2.8	4.3
Income tax payable	4.8	0.5
Consideration for acquisition	2.1	1.8
Secured notes	108.3	102.3
Lease liabilities	2.6	6.9
Liabilities subject to foreclosure	27.4	-
<b>Total current liabilities</b>	<b>297.5</b>	<b>338.0</b>
<b>NON-CURRENT LIABILITIES</b>		
Trade and other payables	46.2	48.5
Borrowings	54.1	38.2
Deferred revenue and advances from customers	1.4	1.4
Joint ventures and associates	0.7	1.0
Deferred tax liabilities	24.3	30.1
Provisions	1.0	1.3
Consideration for acquisition	0.0	0.4
Secured notes	-	-
Lease liabilities	8.6	9.5
<b>Total non-current liabilities</b>	<b>136.4</b>	<b>130.4</b>
<b>Total liabilities</b>	<b>433.9</b>	<b>468.4</b>
<b>EQUITY</b>		
Equity attributable to owners of the parent	67.7	265.4
Non-controlling interest	27.9	29.8
<b>Total equity</b>	<b>95.7</b>	<b>295.2</b>
<b>Total equity and liabilities</b>	<b>529.6</b>	<b>763.6</b>



# Non-IFRS Financial Measures

## Adjusted EBITDA

The company defines adjusted EBITDA as net income/(loss) exclusive of financial income/(costs), income tax benefit/(expense), depreciation, amortization, share-based compensation, and one-time transactional expenses.

Management believes that adjusted EBITDA provides useful supplemental information to investors about the company and its results. Adjusted EBITDA is among the measures used by the management team to evaluate the company's financial and operating performance and make day-to-day financial and operating decisions. In addition, adjusted EBITDA and similarly titled measures are frequently used by competitors, rating agencies, securities analysts, investors and other parties to evaluate companies in the same industry. Management also believes that adjusted EBITDA is helpful to investors because it provides additional information about trends in the company's core operating performance prior to considering the impact of capital structure, depreciation, amortization and taxation on results. Adjusted EBITDA should not be considered in isolation or as a substitute for other measures of financial performance reported in accordance with IFRS. Adjusted EBITDA has limitations as an analytical tool, including:

- Adjusted EBITDA does not reflect changes in, including cash requirements for working capital needs or contractual commitments.
- Adjusted EBITDA does not reflect financial expenses, or the cash requirements to service interest or principal payments on indebtedness, or interest income or other financial income.
- Adjusted EBITDA does not reflect income tax expense or the cash requirements to pay income taxes.
- Although depreciation and amortization are non-cash charges, the assets being depreciated or amortized often will need to be replaced in the future, and adjusted EBITDA does not reflect any cash requirements for these replacements.
- Although share-based compensation is a non-cash charge, adjusted EBITDA does not consider the potentially dilutive impact of share-based compensation.

- Other companies may calculate adjusted EBITDA and similarly titled measures differently, limiting its usefulness as a comparative measure.

The company compensates for the inherent limitations associated with using adjusted EBITDA through disclosure of these limitations, presentation in the combined financial statements in accordance with IFRS and reconciliation of adjusted EBITDA to the most directly comparable IFRS measure, income/(loss) for the period or year.

### Adjusted EBITDA reconciliation from Profit/(Loss) for the period

(\$ Million)	3Q25	3Q26
<b>Profit/(loss) for the period</b>	<b>2.3</b>	<b>(10.0)</b>
Income tax	(3.6)	(4.0)
Financial results	5.6	9.7
D&A	3.8	3.4
Stock-based compensation charges	0.9	0.1
Transaction expenses	-	0.3
<b>Adjusted EBITDA</b>	<b>9.1</b>	<b>(0.6)</b>





 **Bioceres Crop Solutions**

**Contact Us:** Investor Relations [Investorrelations@biocerescrops.com](mailto:Investorrelations@biocerescrops.com) // [Investors.biocerescrops.com](http://Investors.biocerescrops.com)